TransMedics Group (NASDAQ:TMDX) PT Raised to $180.00

TransMedics Group (NASDAQ:TMDX) had its target price hoisted by Piper Sandler from $170.00 to $180.00 in a research report released on Thursday morning, Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also recently weighed in on TMDX. Canaccord Genuity Group increased their price objective on TransMedics Group from $117.00 to $169.00 and gave the stock a buy rating in a report on Thursday. Oppenheimer raised their price target on TransMedics Group from $125.00 to $200.00 and gave the stock an outperform rating in a research note on Thursday. TD Cowen lifted their price target on shares of TransMedics Group from $130.00 to $175.00 and gave the company a buy rating in a report on Friday, June 7th. Morgan Stanley raised their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an equal weight rating in a research report on Monday, July 15th. Finally, Cantor Fitzgerald initiated coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an overweight rating and a $161.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of Moderate Buy and an average target price of $166.88.

TransMedics Group Price Performance

TMDX opened at $150.10 on Thursday. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. The stock’s 50 day simple moving average is $144.02 and its 200 day simple moving average is $111.51. The firm has a market cap of $4.94 billion, a price-to-earnings ratio of -441.47 and a beta of 1.99. TransMedics Group has a 1 year low of $36.42 and a 1 year high of $171.98.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 17.37%. The firm had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter last year, the business earned ($0.03) earnings per share. The business’s revenue was up 117.7% on a year-over-year basis. As a group, analysts predict that TransMedics Group will post 1 earnings per share for the current year.

Insider Activity

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $141.85, for a total value of $1,223,456.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,744,059.55. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other TransMedics Group news, insider Tamer I. Khayal sold 2,960 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $133.10, for a total transaction of $393,976.00. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $2,774,203.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $141.85, for a total value of $1,223,456.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,744,059.55. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $7,401,345 over the last 90 days. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new position in shares of TransMedics Group in the first quarter worth approximately $30,000. Fidelis Capital Partners LLC bought a new position in shares of TransMedics Group during the 1st quarter valued at approximately $35,000. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group in the second quarter valued at $47,000. J.Safra Asset Management Corp increased its position in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the last quarter. Finally, Signaturefd LLC raised its stake in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.